Summary
29.46 0.38(1.31%)10/15/2024
Pfizer Inc. (PFE)
Pfizer Inc. (PFE)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.24 | 0.96 | -2.06 | 1.22 | 13.75 | -11.45 | -4.08 | 16,584.41 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 29.46 | |
| Open | 29.09 | |
| High | 29.74 | |
| Low | 29.09 | |
| Volume | 21,729,600 | |
| Change | 0.36 | |
| Change % | 1.24 | |
| Avg Volume (20 Days) | 25,862,904 | |
| Volume/Avg Volume (20 Days) Ratio | 0.84 | |
| 52 Week Range | 25.20 - 33.92 | |
| Price vs 52 Week High | -13.15% | |
| Price vs 52 Week Low | 16.90% | |
| Range | 1.27 | |
| Gap Up/Down | -0.08 | |
Fundamentals | ||
| Market Capitalization (Mln) | 164,164 | |
| EBIDTA | 9,621,000,192 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.2560 | |
| WallStreet Target Price | 31.37 | |
| Book Value | 16.2840 | |
| Earnings Per Share | -0.0500 | |
| EPS Estimate Current Quarter | 0.5200 | |
| EPS Estimate Next Quarter | 0.4400 | |
| EPS Estimate Current Year | 2.3600 | |
| EPS Estimate Next Year | 2.7600 | |
| Diluted EPS (TTM) | -0.0500 | |
| Revenues | ||
| Profit Marging | -0.0056 | |
| Operating Marging (TTM) | 0.3163 | |
| Return on asset (TTM) | 0.0093 | |
| Return on equity (TTM) | -0.0026 | |
| Revenue TTM | 54,889,000,960 | |
| Revenue per share TTM | 9.7170 | |
| Quarterly Revenue Growth (YOY) | -0.1950 | |
| Quarterly Earnings Growth (YOY) | -0.4340 | |
| Gross Profit (TTM) | 66,233,000,000 | |
| Dividends | ||
| Dividend Share | 1.6500 | |
| Dividend Yield | 0.0600 | |
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 11.6686 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.6451 | |
| Revenue Enterprise Value | 3.4975 | |
| EBITDA Enterprise Value | 21.4072 | |
| Shares | ||
| Shares Outstanding | 5,666,590,208 | |
| Shares Float | 5,657,809,679 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 0.05 | |
| Institutions (%) | 70.15 | |
10/15 11:38 EST - 247wallst.com
3 Top High-Yield Dividend Stocks to Buy in October 2024
As we move further into October, many investors may be looking to identify certain stocks with the potential to provide additional capital appreciation upside, but also some strong dividend income.
3 Top High-Yield Dividend Stocks to Buy in October 2024
As we move further into October, many investors may be looking to identify certain stocks with the potential to provide additional capital appreciation upside, but also some strong dividend income.
10/15 10:47 EST - youtube.com
How to play biotech stocks: Johnson & Johnson, Pfizer
Goldman Sachs senior biotechnology analyst in global investment research Chris Shibutani joins Market Domination Hosts Julie Hyman and Josh Lipton to break down how to play biotech and pharmaceutical stocks. Johnson & Johnson reports earnings on Tuesday, which Shibutani says “typically kicks off earnings season for healthcare, but also for the large-cap pharmas.
How to play biotech stocks: Johnson & Johnson, Pfizer
Goldman Sachs senior biotechnology analyst in global investment research Chris Shibutani joins Market Domination Hosts Julie Hyman and Josh Lipton to break down how to play biotech and pharmaceutical stocks. Johnson & Johnson reports earnings on Tuesday, which Shibutani says “typically kicks off earnings season for healthcare, but also for the large-cap pharmas.
10/15 10:22 EST - reuters.com
Pfizer taps Vanguard veteran for board amid fight with Starboard
Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as it faces pressure from activist hedge fund Starboard Value.
Pfizer taps Vanguard veteran for board amid fight with Starboard
Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as it faces pressure from activist hedge fund Starboard Value.
10/15 06:45 EST - businesswire.com
Tim Buckley Elected to Pfizer's Board of Directors
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the election of Mortimer (“Tim”) J. Buckley to its Board of Directors, effective immediately, following a lengthy and comprehensive search that began in May 2024. Mr. Buckley, age 55, was also appointed to and will join the Governance and Sustainability Committee and the Audit Committee of Pfizer's Board. Following the appointment of Mr. Buckley, the Board will comprise 14 directors, 13 of whom are independent. Mr. Buckley serve.
Tim Buckley Elected to Pfizer's Board of Directors
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the election of Mortimer (“Tim”) J. Buckley to its Board of Directors, effective immediately, following a lengthy and comprehensive search that began in May 2024. Mr. Buckley, age 55, was also appointed to and will join the Governance and Sustainability Committee and the Audit Committee of Pfizer's Board. Following the appointment of Mr. Buckley, the Board will comprise 14 directors, 13 of whom are independent. Mr. Buckley serve.
10/15 06:00 EST - fool.com
Pfizer Is Clashing With Its New Activist Investor. Will It Harm The Stock?
This investor's campaign is stoking some undesirable corporate intrigue.
Pfizer Is Clashing With Its New Activist Investor. Will It Harm The Stock?
This investor's campaign is stoking some undesirable corporate intrigue.
10/15 04:41 EST - fool.com
2 Ultra-High-Yield Dividend Stocks With Total Return Potential of Up to 92% in 12 Months, According to Select Wall Street Analysts
Two supercharged income stocks -- sporting yields of 5.6% and 5.8% -- have the tools and intangibles needed to catapult higher.
2 Ultra-High-Yield Dividend Stocks With Total Return Potential of Up to 92% in 12 Months, According to Select Wall Street Analysts
Two supercharged income stocks -- sporting yields of 5.6% and 5.8% -- have the tools and intangibles needed to catapult higher.
10/14 18:51 EST - zacks.com
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, Pfizer (PFE) stood at $29.08, denoting a -0.27% change from the preceding trading day.
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, Pfizer (PFE) stood at $29.08, denoting a -0.27% change from the preceding trading day.
10/14 14:46 EST - benzinga.com
These 3 Stocks Just Spiked—Buy the Rally or Sell the News?
Selling the news is a common trading strategy in which traders buy a stock in anticipation of expected news, then sell once the event occurs. It's a short-term strategy based on the psychology that the unknown is frequently better or worse than the known.
These 3 Stocks Just Spiked—Buy the Rally or Sell the News?
Selling the news is a common trading strategy in which traders buy a stock in anticipation of expected news, then sell once the event occurs. It's a short-term strategy based on the psychology that the unknown is frequently better or worse than the known.
10/14 10:10 EST - zacks.com
Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi
Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be administered via a pre-filled, auto-injector pen.
Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi
Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be administered via a pre-filled, auto-injector pen.
10/14 10:00 EST - fool.com
Which Pharma Stock Is the Better Bargain Buy: Pfizer or Eli Lilly?
These two stocks will appeal to very different types of investors at the moment.
Which Pharma Stock Is the Better Bargain Buy: Pfizer or Eli Lilly?
These two stocks will appeal to very different types of investors at the moment.
10/14 05:34 EST - fool.com
Prediction: These 2 High-Yield Dividend Stocks Will Outperform the S&P 500 Index in the Coming Decade
Buying these stocks gives you a great chance to beat the benchmark.
Prediction: These 2 High-Yield Dividend Stocks Will Outperform the S&P 500 Index in the Coming Decade
Buying these stocks gives you a great chance to beat the benchmark.
10/12 09:00 EST - fool.com
2 Unstoppable Growth Stocks to Buy Right Now for Less than $200
These businesses are trading at discounts right now.
2 Unstoppable Growth Stocks to Buy Right Now for Less than $200
These businesses are trading at discounts right now.
10/12 06:10 EST - fool.com
2 Incredibly Cheap Big Pharma Stocks to Buy Now
There's doubtlessly some coming uncertainty for both, but the prices are right.
2 Incredibly Cheap Big Pharma Stocks to Buy Now
There's doubtlessly some coming uncertainty for both, but the prices are right.
10/12 05:26 EST - fool.com
3 Reliable Dividend Stocks With Yields Above 5% That You Can Buy With Less Than $100 Right Now
You don't need to be rich to put your money to work on Wall Street.
3 Reliable Dividend Stocks With Yields Above 5% That You Can Buy With Less Than $100 Right Now
You don't need to be rich to put your money to work on Wall Street.
10/11 15:32 EST - youtube.com
Bullish Underdogs and Big Winners: PYPL, PFE & AMZN
Andrew Arons with Synergy Advisory Management remains bullish on the state of the markets, crediting A.I. stocks and the Fed's rate cut.
Bullish Underdogs and Big Winners: PYPL, PFE & AMZN
Andrew Arons with Synergy Advisory Management remains bullish on the state of the markets, crediting A.I. stocks and the Fed's rate cut.
10/11 13:29 EST - marketwatch.com
Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for constant intravenous infusions or injections, which are painful as well as inconvenient.
Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for constant intravenous infusions or injections, which are painful as well as inconvenient.
10/11 13:27 EST - reuters.com
US FDA approves Pfizer's drug for rare bleeding disorder
The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding disorder called hemophilia, the company said on Friday.
US FDA approves Pfizer's drug for rare bleeding disorder
The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding disorder called hemophilia, the company said on Friday.
10/11 13:23 EST - businesswire.com
U.S. FDA Approves Pfizer's HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII (FVIII) inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX (FIX) inhibitors. HYMPAVZI is the first.
U.S. FDA Approves Pfizer's HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII (FVIII) inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX (FIX) inhibitors. HYMPAVZI is the first.
10/11 08:45 EST - fool.com
An Activist Investor Just Bought $1 Billion Worth of Pfizer. Here's What It Means for the Stock
There may be changes coming to this company, if the activists get their way.
An Activist Investor Just Bought $1 Billion Worth of Pfizer. Here's What It Means for the Stock
There may be changes coming to this company, if the activists get their way.
10/10 17:51 EST - fool.com
Why Pfizer Stock Tumbled by Nearly 3% on Thursday
The company's latest institutional shareholder has made some troubling allegations against it.
Why Pfizer Stock Tumbled by Nearly 3% on Thursday
The company's latest institutional shareholder has made some troubling allegations against it.